No connection

Search Results

FMS vs JAZZ

FMS
Fresenius Medical Care AG
BULLISH
Price
$22.77
Market Cap
$12.44B
Sector
Healthcare
AI Confidence
75%
JAZZ
Jazz Pharmaceuticals plc
NEUTRAL
Price
$194.20
Market Cap
$11.96B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FMS
11.56
JAZZ
--
Forward P/E
FMS
5.62
JAZZ
7.74
P/B Ratio
FMS
0.81
JAZZ
2.76
P/S Ratio
FMS
0.63
JAZZ
2.8
EV/EBITDA
FMS
6.25
JAZZ
8.71

Profitability

Gross Margin
FMS
25.62%
JAZZ
91.67%
Operating Margin
FMS
11.68%
JAZZ
27.06%
Profit Margin
FMS
4.98%
JAZZ
-8.34%
ROE
FMS
7.93%
JAZZ
-8.47%
ROA
FMS
3.62%
JAZZ
5.38%

Growth

Revenue Growth
FMS
-0.3%
JAZZ
10.1%
Earnings Growth
FMS
420.0%
JAZZ
3.2%

Financial Health

Debt/Equity
FMS
0.76
JAZZ
1.26
Current Ratio
FMS
1.26
JAZZ
1.86
Quick Ratio
FMS
0.85
JAZZ
1.46

Dividends

Dividend Yield
FMS
3.58%
JAZZ
--
Payout Ratio
FMS
42.76%
JAZZ
0.0%

AI Verdict

FMS BULLISH

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Strengths
Significant undervaluation relative to Graham Number and Intrinsic Value
Strong earnings recovery with YoY growth of 420%
Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)
Risks
Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum
Severe bearish technical trend (0/100 score)
Low insider sentiment (40/100) suggesting lack of internal confidence
JAZZ NEUTRAL

JAZZ presents a stark contradiction between fundamental health and market valuation, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits an extremely attractive valuation with a Forward P/E of 7.74 and a PEG ratio of 0.63, its internal financial health is deteriorating, evidenced by negative profit margins and ROE. Despite a massive 1-year price surge of 90.3%, bearish insider sentiment and a low technical trend score suggest a potential peak or internal instability. The stock currently functions as a high-risk value play where analyst optimism clashes with poor deterministic health metrics.

Strengths
Exceptional Gross Margin of 91.67%
Highly attractive Forward P/E of 7.74
Undervalued PEG ratio of 0.63
Risks
Critically low Piotroski F-Score (2/9) indicating weak financial trends
Negative Profit Margin (-8.35%) and negative ROE (-8.47%)
Bearish insider activity with $15.3M in sales and zero buys

Compare Another Pair

FMS vs JAZZ: Head-to-Head Comparison

This page compares Fresenius Medical Care AG (FMS) and Jazz Pharmaceuticals plc (JAZZ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile